AI assistant
Aprea Therapeutics, Inc. — Director's Dealing 2021
Jul 2, 2021
35269_dirs_2021-07-01_2924776b-48f1-40c4-83f3-1cfba730a181.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-06-30
Reporting Person: Kelly Michael Aaron (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-30 | Common Stock | A | 4610 | — | Acquired | 4610 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-30 | Stock Option (Right to Buy) | $4.88 | A | 22750 | Acquired | 2031-06-30 | Common Stock (22750) | Direct |
Footnotes
F1: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.